Health Care & Life Sciences » Pharmaceuticals | Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc. | Ownership

Companies that own Corvus Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
OrbiMed Advisors LLC
5,967,584
20.44%
0
0.68%
06/30/2018
Fidelity Management & Research Co.
2,478,297
8.49%
-73,823
0%
06/30/2018
T. Rowe Price Associates, Inc.
2,000,099
6.85%
-4,576
0%
06/30/2018
BVF Partners LP
1,890,507
6.48%
-63,747
1.4%
06/30/2018
BlackRock Fund Advisors
977,312
3.35%
339,066
0%
06/30/2018
The Vanguard Group, Inc.
639,081
2.19%
36,398
0%
06/30/2018
Rock Springs Capital Management LP
575,000
1.97%
0
0.23%
06/30/2018
Cowen Investment Management LLC
534,397
1.83%
534,397
2.48%
06/30/2018
Ecor1 Capital LLC
450,400
1.54%
-19,300
0.51%
06/30/2018
Millennium Management LLC
345,574
1.18%
-259,729
0.01%
06/30/2018

About Corvus Pharmaceuticals

View Profile
Address
863 Mitten Road
Burlingame California 94010
United States
Employees -
Website http://www.corvuspharma.com
Updated 07/08/2019
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of small molecule and antibody agents that target crucial enzymes and proteins in the immune system to treat patients with cancer. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.